Deck 23: Cytokines and Biological Modifiers

Question 1

Which of the following is an outcome of IL-1 release from activated immune cells?

A) Cleavage of viral RNA
B) Prevention of microbial growth
C) Increased production of antibodies
D) Downregulation of adhesion molecules

Answer 1

Prevention of microbial growth

Question 2

Which is one disadvantage to cell-based anticancer vaccines?

A) Vaccines often must be patient-specific.
B) Vaccines may react with other host cells.
C) Vaccines with live cells do not have long-lasting effects.
D) Vaccines are less effective because they use allogeneic cells.

Answer 2

Vaccines often must be patient-specific.

Question 3

What is one role that type I interferons play in the eradication of viral infections?

A) Inhibit viral uncoating
B) Inhibit viral protein synthesis
C) Block viral entry into host cells
D) Block release of viral progeny from host cells

Answer 3

Inhibit viral protein synthesis

Question 4

NY-ESO-1 would be a beneficial addition to a cancer vaccine because:

A) It stimulates macrophages
B) It stimulates the production NK cells
C) It stimulates both CD4 and CD8 T cells
D) It stimulates a strong antibody response

Question 5

A defect in production of cryopyrin leads to:

A) Increased synthesis of IL-2
B) Increased synthesis of TNF
C) Increased synthesis of IL-1b
D) Increased synthesis of IL-1a

Question 6

Oprelvekin increases levels of:

A) Platelets
B) Neutrophils
C) Macrophages
D) Red blood cells

Question 7

What is the mechanism of action of the sipuleucel-T prostate cancer vaccine?

A) Dendritic cells are incubated with a fusion protein containing prostate specific antigen (PSA) and GM-CSF.
B) A plasmid that codes for an antibody that expresses prostate specific antigen (PSA), and dendritic cells present PSA to T cells.
C) A single B cell clone that is tumor specific is grown in the lab and infused into the patient to produce large amounts of tumor specific antibody.
D) Patient tumor cells are exposed to a viral vector containing a gene for prostate specific antigen (PSA), and then the tumor cells are infused into the patient to stimulate an immune response.

Question 8

Recombinant IL-2 administration is appropriate for the treatment of:

A) HIV
B) Cancer
C) Arthritis
D) Transplant patients

Question 9

Which of the following may be administered to treat rheumatoid arthritis?
I. Infliximab
II. Adalimumab
III. Canakinumab

A) I only
B) III only
C) I and II
D) II and III
E) I, II, and III

Question 10

Which of the following is a marker for melanoma?

A) AFP
B) CEA
C) MART-1
D) Sialyl Tn antigen